Ameritas Investment Partners, Inc. Akebia Therapeutics, Inc. Transaction History
Ameritas Investment Partners, Inc.
- $2.98 Billion
- Q4 2024
A detailed history of Ameritas Investment Partners, Inc. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 20,380 shares of AKBA stock, worth $42,798. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,380
Previous 20,380
-0.0%
Holding current value
$42,798
Previous $26,000
42.31%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding AKBA
# of Institutions
130Shares Held
63.3MCall Options Held
67.1KPut Options Held
203K-
Black Rock Inc. New York, NY11.6MShares$24.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$22.9 Million0.0% of portfolio
-
State Street Corp Boston, MA6.3MShares$13.2 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$12.1 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA4.8MShares$10.1 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $386M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...